Show simple item record

dc.contributor.authorGarcía González, Jorge José 
dc.contributor.authorRUIZ BAÑOBRE, JUAN 
dc.contributor.authorAfonso Afonso, Francisco Javier 
dc.contributor.authorAmenedo-Gancedo, Margarita
dc.contributor.authorAreses Manrique, María Carmen 
dc.contributor.authorCampos Balea, Begoña 
dc.contributor.authorCasal Rubio, Joaquín 
dc.contributor.authorFernández Nuñez, Natalia 
dc.contributor.authorFirvida Perez, Jose Luis 
dc.contributor.authorLazaro Quintela, Martín 
dc.contributor.authorPérez Parente, Diego 
dc.contributor.authorCrama, Leonardo
dc.contributor.authorRuiz-Gracia, Pedro
dc.contributor.authorSantomé-Couto, Lucía
dc.contributor.authorLeón Mateos, Luis Ángel 
dc.date.accessioned2022-03-17T08:20:39Z
dc.date.available2022-03-17T08:20:39Z
dc.date.issued2020
dc.identifier.issn2077-0383
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/32635291es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/16315
dc.description.abstractThe combination of programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors with chemotherapy has emerged as a promising therapeutic option for advanced non-small-cell lung cancer (NSCLC). The aim of this meta-analysis was to evaluate the efficacy of the combined strategy in this setting. For this purpose, we performed a literature search of randomized controlled trials comparing PD-(L)1 inhibitors plus platinum-based chemotherapy versus chemotherapy alone in stage IV NSCLC patients. Seven clinical trials with 4562 patients were included. In the intention-to-treat wildtype population, PD-(L)1 inhibitor plus chemotherapy was significantly associated with improved progression-free survival (PFS) (Hazard ratio (HR) = 0.61, 95% confidence interval (CI): 0.57-0.65, p < 0.001) and overall survival (OS) (HR = 0.76, 95% CI: 0.67-0.86; p < 0.001) compared to chemotherapy. A significantly higher overall response rate (ORR) was also observed with the combined strategy (Odds ratio (OR) = 2.12, 95% CI: 1.70-2.63, p < 0.001). Furthermore, in all the analyzed subgroups, addition of PD-(L)1 inhibitors to chemotherapy significantly improved efficacy endpoints. Specifically, stratification according to PD-L1 expression revealed a benefit across all patients, regardless of their PFS status. In conclusion, PD-(L)1 blockade added to standard platinum-based chemotherapy significantly improved PFS, OS, and ORR in the up-front treatment of advanced NSCLC.en
dc.rightsAtribución 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titlePD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysisen
dc.typeJournal Articlees
dc.authorsophosGarcía-González, Jorge;Ruiz-Bañobre, Juan;Afonso-Afonso, Francisco J.;Amenedo-Gancedo, Margarita;Areses-Manrique, María Del Carmen;Campos-Balea, Begoña;Casal-Rubio, Joaquín;Fernández-Núñez, Natalia;Fírvida Pérez, José Luis;Lázaro-Quintela, Martín;Pérez Parente, Diego;Crama, Leonardo;Ruiz-Gracia, Pedro;Santomé-Couto, Lucía;León-Mateos, Luis
dc.identifier.doi10.3390/jcm9072093
dc.identifier.pmid32635291
dc.identifier.sophos36407
dc.issue.number7es
dc.journal.titleJournal of Clinical Medicinees
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Ferrol – Complexo Hospitalario Universitario de Ferrol::Oncoloxía médicaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Oncoloxía médicaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Ourense, Verín e O Barco de Valdeorras - Complexo Hospitalario Universitario de Ourense::Oncoloxía médicaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Vigo - Complexo Hospitalario Universitario de Vigo::Oncoloxía médicaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Lugo, Cervo e Monforte de lemos - Complexo Hospitalario Universitario Lucus Augusti::Oncoloxía médicaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)es
dc.page.initial2093es
dc.relation.publisherversionhttps://mdpi-res.com/d://attachment/jcm/jcm-09-02093/article://deploy/jcm-09-02093-v2.pdfes
dc.rights.accessRightsopenAccess
dc.subject.keywordCHUFes
dc.subject.keywordCHUSes
dc.subject.keywordCHUOes
dc.subject.keywordCHUVIes
dc.subject.keywordHULAes
dc.subject.keywordIDISes
dc.typefidesArtículo de Revisiónes
dc.typesophosArtículo de Revisiónes
dc.volume.number9es


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
Except where otherwise noted, this item's license is described as Atribución 4.0 Internacional